[Use of long-acting contraceptives in the treatment of mastopathy].

Effects of long-acting contraceptives on mammary glands of patients with diffuse fibrocystic mastopathy were under study. A total of 206 women aged 17 to 38 were examined. In 50 of them fibrocystic mastopathy was detected by palpation, non-contrast mammography, and ultrasonic examination.

[The Depo-Provera treatment of mastopathy patients].

35 women with diffuse fibrous-cystic mastopathy were treated with gestagen slow-releasing drug "Depo-Provera". Use of the drug made part of the patients feel better and promoted regression of objective signs of the disease. Conclusion was made that administration of the drug in mastopathy caused by hormonal disorders is pathogenetically substantiated method of treatment.

[The effect of nizoral on the function of the hypothalamo-hypophyseal-ovarian system in virilism].

A study is presented of the effect of nisoral on the hypothalamo-pituitary-ovarian system in 25 patients with hyperandrogenism (ovarian in 11, suprarenal in 14). It was established that most patients with oligomenorrhea and anovulation showed a restoration of the menstrual cycle after the 2-3 treatment courses and also absence of progression and reduction of the rate of pathological hair growth. After nisoral treatment the testosterone level decreased while estradiol and progesterone increased, gonadotropins remained unchanged, urinary excretion of 17-ketosteroids reduced.

[The treatment of the climacteric syndrome in women suffering from Itsenko-Cushing disease and primary obesity].

Results are reported of an investigation of the hypothalamo-pituitary-ovarian-adrenal system in 51 women suffering of Itsenko-Cushing disease, primary obesity and menopausal syndrome. It was found that with onset of the menopause there occurs an increase of the concentration of lutropin, follitropin, testosterone and a reduction of the level of estradiol as in the control group. At the same time the level of prolactin and cortisol was increased as compared with the control group.